These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34269012)

  • 41. Quadruple therapy for asymptomatic COVID-19 infection patients.
    Wang L; Xu X; Ruan J; Lin S; Jiang J; Ye H
    Expert Rev Anti Infect Ther; 2020 Jul; 18(7):617-624. PubMed ID: 32362193
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir.
    Brandariz-Nuñez D; Correas-Sanahuja M; Guarc E; Picón R; García B; Gil R
    Med Clin (Barc); 2020 Oct; 155(7):281-287. PubMed ID: 32718719
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2.
    Liu J; Du C; Pu L; Xiang P; Xiong H; Xie W; Chen Z; Li A
    BMC Infect Dis; 2021 Aug; 21(1):885. PubMed ID: 34461841
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Comparative Study of Antiretroviral (Lopinavir/Ritonavir) and Remdesivir Used in the Pandemic in Iraq on the Clinical Outcome in Patients with SARS-CoV-2.
    Alabdalaali MM; Hadi AM
    Arch Razi Inst; 2023 Jun; 78(3):935-941. PubMed ID: 38028857
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2.
    Thakur A; Tan SPF; Chan JCY
    Clin Pharmacol Ther; 2020 Dec; 108(6):1176-1184. PubMed ID: 32767755
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
    Wang N; Zhan Y; Zhu L; Hou Z; Liu F; Song P; Qiu F; Wang X; Zou X; Wan D; Qian X; Wang S; Guo Y; Yu H; Cui M; Tong G; Xu Y; Zheng Z; Lu Y; Hong P
    Cell Host Microbe; 2020 Sep; 28(3):455-464.e2. PubMed ID: 32707096
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir.
    Yin G; Zhang C; Jin H
    JMIR Public Health Surveill; 2020 Jul; 6(3):e19538. PubMed ID: 32589146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.
    Huang YQ; Tang SQ; Xu XL; Zeng YM; He XQ; Li Y; Harypursat V; Lu YQ; Wan Y; Zhang L; Sun QZ; Sun NN; Wang GX; Yang ZP; Chen YK
    Front Pharmacol; 2020; 11():1071. PubMed ID: 32765274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent progress of antiviral therapy for coronavirus disease 2019.
    Zhao M; Zhang J; Li H; Luo Z; Ye J; Xu Y; Wang Z; Ye D; Liu J; Li D; Wang M; Wan J
    Eur J Pharmacol; 2021 Jan; 890():173646. PubMed ID: 33190802
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.
    Wang Z; Chen X; Lu Y; Chen F; Zhang W
    Biosci Trends; 2020 Mar; 14(1):64-68. PubMed ID: 32037389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.
    Lowe DM; Brown LK; Chowdhury K; Davey S; Yee P; Ikeji F; Ndoutoumou A; Shah D; Lennon A; Rai A; Agyeman AA; Checkley A; Longley N; Dehbi HM; Freemantle N; Breuer J; Standing JF;
    PLoS Med; 2022 Oct; 19(10):e1004120. PubMed ID: 36260627
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series.
    Luo P; Zheng JL; Liu Y; Qiu L; Liu XL; Xue HY; Liu D; Li J
    Clin Med (Lond); 2021 Jan; 21(1):e80-e83. PubMed ID: 33355217
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
    Drożdżal S; Rosik J; Lechowicz K; Machaj F; Kotfis K; Ghavami S; Łos MJ
    Drug Resist Updat; 2020 Dec; 53():100719. PubMed ID: 32717568
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice.
    Levy C; Lassailly G; Parmentier E; Duburcq T; Mathurin P; Poissy J
    Am J Gastroenterol; 2020 Oct; 115(10):1716-1718. PubMed ID: 32858566
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series.
    Lepage MA; Rozza N; Kremer R; Grunbaum A
    Clin Toxicol (Phila); 2021 Jul; 59(7):644-647. PubMed ID: 33641562
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
    Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19.
    Apaydın ÇB; Çınar G; Cihan-Üstündağ G
    Curr Drug Targets; 2021; 22(17):1986-2005. PubMed ID: 33588727
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A global treatments for coronaviruses including COVID-19.
    Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M
    J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review.
    Qomara WF; Primanissa DN; Amalia SH; Purwadi FV; Zakiyah N
    Int J Gen Med; 2021; 14():8557-8571. PubMed ID: 34849001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.